← Back to Clinical Trials
Recruiting NCT06416293

NCT06416293 Widening Aims and Giving Patients a Voice for Expanded Structures in Breast Cancer Care Jointly Developed by Patients and Physicians

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06416293
Status Recruiting
Phase
Sponsor University Hospital Augsburg
Condition Breast Cancer
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2022-04-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Questionnaire patientsQuestionnaire physicians

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2022-04-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this BZKF project is to record the current care structure for breast cancer patients in order to use this as a basis for developing possible future models for improvement. The active involvement of representatives of regional and national patient organizations in the creation of a patient-based and patient-oriented survey ensures that the needs of patients are the focus. In addition to and in contrast to other projects, relevant questions are explicitly addressed not only to patients but also to physicians in order to identify and specify the interfaces between patient wishes/suggestions and to develop clinical consequences for care. The first objective is to survey the "current situation" by recording the current care structure for breast cancer. The focus is on the survey of both groups on patient-physician communication, time management and coping strategies. By planning the future harmonization of national data structures, the basis is created for the long-term goal of an improved "target", a concept developed jointly by physicians and patients for an improved communication and care structure that focuses on the patient.

Eligibility Criteria

Inclusion Criteria (patients): * Breast cancer or DCIS * women and men aged 18 years and older Exclusion Criteria (patients): * women and men \< 18 years * no histologically confirmed breast cancer or DCIS diagnosis Inclusion Criteria (physicians): \- Treatment of breast cancer patients

Contact & Investigator

Central Contact

Nina Ditsch, Prof.

✉ nina.ditsch@uk-augsburg.de

📞 +49 821 400 15809

Principal Investigator

Nina Ditsch, Prof.

PRINCIPAL INVESTIGATOR

University Hospital Augsburg

Frequently Asked Questions

Who can join the NCT06416293 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06416293 currently recruiting?

Yes, NCT06416293 is actively recruiting participants. Contact the research team at nina.ditsch@uk-augsburg.de for enrollment information.

Where is the NCT06416293 trial being conducted?

This trial is being conducted at Augsburg, Germany.

Who is sponsoring the NCT06416293 clinical trial?

NCT06416293 is sponsored by University Hospital Augsburg. The principal investigator is Nina Ditsch, Prof. at University Hospital Augsburg. The trial plans to enroll 2,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology